Journal of Cardiac Failure最新文献

{"title":"Innovate and Translate: Highlights from THT (Technology and Heart Failure Therapeutics) 2025 in Boston.","authors":"Elena M Donald, Alexander G Hajduczok, Rachel Goodman, Shazli Khan, Daniel Burkhoff, Aditi Nayak","doi":"10.1016/j.cardfail.2025.02.012","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.02.012","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity in Treatment Effects in the Reduction of Dietary Sodium to Less than 100 mmol in Heart Failure (SODIUM-HF): A Secondary Post-hoc Analysis.","authors":"Fernando G Zampieri, Sarah Rathwell, Finlay A McAlister, Heather Ross, Jorge Escobedo, Clara Saldarriaga, Eloisa Colin-Ramirez, Richard W Troughton, Peter Macdonald, Wendimagegn Alemayehu, Justin A Ezekowitz","doi":"10.1016/j.cardfail.2025.01.027","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.01.027","url":null,"abstract":"<p><strong>Objectives: </strong>Explore the presence of heterogeneity in treatment effects (HTE) in the Study of Dietary Intervention of Sodium Under100 mmol in Heart Failure (SODIUM-HF) trial using a risk-effect-based approach.</p><p><strong>Background: </strong>SODIUM-HF compared usual care with dietary sodium restriction in heart failure patients (HF) and produced neutral results for the primary endpoint. HTE analysis could enhance the original findings.</p><p><strong>Methods: </strong>HTE was assessed using a risk-based approach based on the Meta-Analysis Global Group in Chronic (MAGGIC) HF risk score. Interaction between MAGGIC quartiles and outcomes was assessed using a Bayesian regression model with neutral priors. Primary endpoint was the same for the original trial (composite of cardiovascular-related admission to hospital, cardiovascular-related emergency department visit, or all-cause death within 12 months in the intention-to-treat population); KCCQ was the secondary endpoint.</p><p><strong>Results: </strong>806 patients were included. MAGGIC quartiles used for the risk-based analyses were 0.036 to 0.102 (low), >0.102 to 0.147 (medium-low), >0.147 to 0.209 (medium-high), and >0.209 to 0.591 (high). There was very strong evidence for the interaction between MAGGIC quartile and intervention (Bayes Factor of 68). There was a strong suggestion of association between intervention arm and a lower occurrence of the primary endpoint for the medium-low MAGGIC quartile (>0.98 probability), and a suggestion that the intervention was associated with more frequent occurrence of primary endpoint in the high MAGGIC quartile (probability of benefit of 0.06). Suggestion of HTE was also found for KCCQ with a strong suggestion of benefit for the intervention for those in the lowest MAGGIC quartilex.</p><p><strong>Conclusions: </strong>HTE effects in the SODIUM-HF trial is probable. Further trials in sodium retention may benefit of incorporating this information.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Ketosis for Heart Failure: A State-of-the-Art-Review.","authors":"Nandan Kodur, Christopher Nguyen, W H Wilson Tang","doi":"10.1016/j.cardfail.2025.01.028","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.01.028","url":null,"abstract":"<p><p>Heart failure is characterized by an energy-deprived heart, and in recent years it has been found that the failing heart increases ketone body oxidation to meet its energy demands. Accumulating evidence suggests that this metabolic adaptation is cardioprotective, suggesting that interventions that boost blood ketone levels could aid the failing heart. Indeed, multiple small clinical trials with short-term follow up have demonstrated that supplying the failing heart with exogenous ketone bodies may improve myocardial function across various manifestations of heart failure. As such, therapeutic ketosis, which is a metabolic state in which blood ketone levels are mildly elevated, could have great potential to ameliorate heart failure. Therapeutic ketosis can be achieved endogenously via exercise or dietary practices, exogenously via supplementation with ketone bodies, or pharmacologically via treatment with a sodium-glucose cotransporter-2 inhibitor. Although ketosis-inducing practices cannot be routinely recommended to patients with heart failure at this time due to a lack of robust data regarding the long-term benefits and risks, anecdotal evidence suggests that some patients have begun to adopt ketosis-inducing practices, so it is important for clinicians to be aware of how to optimally manage patients who are in therapeutic ketosis. In this review, we discuss myocardial ketone metabolism in heart failure, the current evidence for therapeutic ketosis in patients with heart failure, a framework to distinguish between therapeutic ketosis and the pathologic state of ketoacidosis, and practical considerations for managing patients adhering to ketosis-inducing practices.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extending the reach: Ambulatory Specialty Palliative Care for People with Heart Failure.","authors":"Arden O'Donnell, Laura P Gelfman","doi":"10.1016/j.cardfail.2025.02.010","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.02.010","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking Prescription Patterns: The Persistent Challenge of GDMT Underuse.","authors":"Amitai Segev, Nima Moghaddam","doi":"10.1016/j.cardfail.2025.02.011","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.02.011","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Environmental Temperature on the Occurrence of Driveline Infection in LVAD Patients.","authors":"Filippo Calì, Alberto Pinsino, Annamaria Ladanyi, Giulio M Mondellini, Changhee Lee, Gabriel T Sayer, Yuji Kaku, Nir Uriel, Koji Takeda, Justin G Aaron, Melana Yuzefpolskaya, Paolo C Colombo","doi":"10.1016/j.cardfail.2025.01.024","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.01.024","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences Between Ischemic and Non-Ischemic Cardiomyopathy in Heart Failure Related Cardiogenic Shock.","authors":"Jason Feinman, Matthew I Tomey, Michael G Palazzolo, Miguel Martillo, Maria Ronquillo, Noah Moss, Gregory Serrao, Erin A Bohula, David D Berg, Sean van Diepen, Jason N Katz, Meshe D Chonde, Sunit-Preet Chaudhry, Alvin J George, Daniel Gerber, Michael J Goldfarb, Norma M Keller, Michael C Kontos, Daniel B Loriaux, Connor G O'Brien, Barbara A Pisani, Alastair Proudfoot, Kiran Sidhu, Shashank S Sinha, Lakshmi Sridharan, Natalie Tapaskar, Alexander Thomas, Andrea D Thompson, David A Morrow, Umesh Gidwani, Evan Leibner","doi":"10.1016/j.cardfail.2025.01.020","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.01.020","url":null,"abstract":"<p><strong>Background: </strong>Heart failure-related cardiogenic shock (HF-CS) accounts for a growing proportion of cardiogenic shock (CS) related admissions to contemporary cardiac intensive care units. Limited data exists comparing non-ischemic (NICM) and ischemic cardiomyopathies (ICM) in this setting.</p><p><strong>Methods and results: </strong>We sought to examine the differences in patient characteristics, in-hospital treatments, and outcomes among individuals admitted with ICM and NICM HF-CS. The study population included CS admissions within the Critical Care Cardiology Trials Network registry from 2017 to 2022. CS due to acute myocardial infarction or secondary causes was excluded. Admission characteristics, in-hospital treatments, and outcomes were captured. The primary outcome of all-cause in-hospital mortality for ICM versus NICM was compared using multivariable logistic regression. 2,463 hospital admissions for HF-CS including 902 (36.6%) admissions with ICM and 1561 (63.4%) admissions with NICM were included. Patients with ICM more frequently had pre-existing comorbidities, pre-admission cardiac arrest, and higher Sequential Organ Failure Assessment scores. Use of inotropes and temporary mechanical circulatory support were similar; however, the rates of mechanical ventilation and renal replacement therapies were higher for ICM. Patients with ICM were less likely to undergo cardiac transplantation, but had similar rates of durable left ventricular assist device implantation. After multivariable adjustment, patients with ICM were significantly more likely to die during the index hospitalization (OR 1.56, 95% CI 1.26-1.93; p <0.001).</p><p><strong>Conclusions: </strong>Among patients admitted to CICUs with HF-CS, patients with ICM were sicker, less likely to undergo cardiac transplantation, and more likely to die when compared with patients with NICM.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of initiation with sacubitril/valsartan on blood neurodegeneration markers in HFrEF.","authors":"Suriya Prausmüller, Raphael Wurm, Markus Ponleitner, Elisabeth Stögmann, Martin Hulsmann, Noemi Pavo","doi":"10.1016/j.cardfail.2025.01.021","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.01.021","url":null,"abstract":"<p><strong>Background: </strong>Sacubitril/valsartan is a key therapy for heart failure with reduced ejection fraction (HFrEF). However, concerns remain regarding its potential impact on cognitive function since neprilysin inhibition may influence amyloid-β (Aβ) metabolism. This study evaluates the effect of sacubitril/valsartan on plasma biomarkers of neurodegeneration.</p><p><strong>Methods: </strong>Plasma neuromarkers, i.e. Aβ40, Aβ42, neurofilament light chain (NfL), and total tau (t-tau) were measured at baseline, 3 months, and 1 year after sacubitril/valsartan initiation using the single-molecule array (SIMOA) technology in a HFrEF cohort from a prospective registry with biobank. Comparisons were made for baseline vs. 3 months and baseline vs 1-year follow-up.</p><p><strong>Results: </strong>A total of 31 HFrEF patients (median age: 61 years, 74% male, NT-proBNP: 2333 pg/ml) were included. Aβ40 increased transiently at 3 months [228.6 pg/ml (Q1-Q3: 157.8-321.1) vs. 138.8 (110.0-202.2), p < 0.001] but remained unchanged at 1 year [215.0 (106.5-290.9), p = 0.052]. Aβ42 remained stable [9.90 (6.67-12.49) and 8.43 (5.57-11.86) vs. 7.84 (6.50-11.02) pg/ml, p = 0.108 and 0.771], resulting in a reduced Aβ42/Aβ40 ratio at both follow-ups [0.039 (0.036-0.049) at 3 months, p < 0.001; 0.048 (0.041-0.060) at 1 year, p = 0.026 vs. 0.055 (0.052-0.061)]. Total tau remained unchanged [1.13 (0.91-1.90) and 1.21 (0.85-1.65) vs. 1.03 (0.82-1.53) pg/ml, p = 0.068 and 0.188], while NfL increased at 1 year [28.3 (16.5-78.6) vs. 22.6 (15.1-46.9) pg/ml, p = 0.013], with no short-term change [25.3 (15.0-51.3), p = 0.502].</p><p><strong>Conclusion: </strong>Sacubitril/valsartan therapy in HFrEF patients leads to a transient increase in Aβ40 and a sustained reduction in the Aβ42/Aβ40 ratio. Stable t-tau and short-term stable NfL levels provide reassurance regarding the absence of immediate neuronal injury, while an NfL increase observed at 1 year may indicate ongoing heart failure progression rather than direct neurotoxicity. These findings highlight the need for cautious interpretation of the Aβ42/Aβ40 ratio in neurocognitive assessments among patients treated with ARNi. Further studies are warranted to clarify the long-term cognitive implications of sacubitril/valsartan in HFrEF.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and Prognostic Significance of Acute Non-Cardiac Organ Dysfunction across Cardiogenic Shock Subtypes: Varshney et al; Non-Cardiac Organ Dysfunction in CS.","authors":"Anubodh S Varshney, Michael G Palazzolo, Christopher F Barnett, Erin A Bohula, James A Burke, Sunit-Preet Chaudhry, Meshe D Chonde, Shahab Ghafghazi, Daniel A Gerber, Benjamin Kenigsberg, Michael C Kontos, Younghoon Kwon, Patrick R Lawler, Daniel B Loriaux, Venu Menon, Elliott Miller, Connor G O'Brien, Alexander I Papolos, Siddharth M Patel, Brian J Potter, Rajnish Prasad, Kevin S Shah, Shashank S Sinha, Michael A Solomon, Andrea Thompson, Jeffrey J Teuteberg, Sean van Diepen, David A Morrow, David D Berg","doi":"10.1016/j.cardfail.2024.12.017","DOIUrl":"https://doi.org/10.1016/j.cardfail.2024.12.017","url":null,"abstract":"<p><strong>Background: </strong>The epidemiology and prognostic significance of acute non-cardiac organ dysfunction across cardiogenic shock (CS) subtypes are not well-defined.</p><p><strong>Methods: </strong>CS admissions from 2017-2022 in the Critical Care Cardiology Trials Network Registry were classified as acute myocardial infarction-related CS (AMI-CS), acute-on-chronic heart failure-related CS (AoC HF-CS), or de novo HF-CS, and categorized as having at least moderate respiratory, kidney, liver, and/or neurologic dysfunction using established criteria. Burden of organ dysfunction was defined as no organ dysfunction (NOD), single organ dysfunction (SOD), or multi (≥2) organ dysfunction (MOD). Multivariable models were used to evaluate associations of burden and type of non-cardiac organ dysfunction with in-hospital death.</p><p><strong>Results: </strong>Among 3,904 CS admissions, 29.4% had AMI-CS, 50.9% had AoC HF-CS, and 19.7% had de novo HF-CS. AMI-CS and de novo HF-CS had greater prevalence of MOD (35.0% and 33.9%, respectively) compared with AoC HF-CS (23.1%; p<0.01). In-hospital mortality was higher with greater burden of organ dysfunction in the overall CS cohort (SOD vs. NOD: adjusted odds ratio [aOR] for in-hospital death 2.5, 95% confidence interval [CI] 2.0-3.2; MOD vs. NOD: aOR 6.5, 95% CI 5.1-8.2) and across each CS subtype. Kidney dysfunction was the most prognostically important form of organ dysfunction in the overall cohort (aOR 4.1, 95% CI 3.4-5.0) and for each CS subtype.</p><p><strong>Conclusion: </strong>Admissions for AoC HF-CS had a lower burden of acute non-cardiac organ dysfunction compared with admissions for de novo HF-CS and AMI-CS. However, acute non-cardiac organ dysfunction burden was similarly adversely prognostic across all CS subtypes.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inertia Is Not an Option: Laying the Foundation for a Consensus on the Assessment of Kidney Function in Acute Decompensated Heart Failure.","authors":"Isabella Cavagna, Mona Fiuzat, Anuradha Lala, James Januzzi, William Abraham, Matthew Dimond, Marvin Konstam, Christopher O'Connor, Maria Rosa Costanzo","doi":"10.1016/j.cardfail.2025.01.025","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.01.025","url":null,"abstract":"<p><p>none.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}